Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Asian Pac J Cancer Prev ; 25(5): 1589-1598, 2024 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-38809630

RESUMO

INTRODUCTION: Diagnosis of the majority of hepatocellular carcinoma (HCC) patients occurs at intermediate to advanced stages, with a few curative therapeutic options being available. It is therefore strongly urgent to discover additional adjuvant therapy for this lethal malignancy. This study aimed to assess the effectiveness of curcumin (C), piperine (P) and taurine (T) combination as adjuvant agents on serum levels of IFN-γ, immunophenotypic and molecular characterization of mononuclear leukocytes (MNLs) in HCC patients treated with Transarterial chemoembolization (TACE). PATIENTS AND METHODS: Serum and MNLs were collected from 20 TACE-treated HCC patients before (baseline-control samples) and after treatment with 5 g curcumin capsules , 10 mg piperine and 0.5 mg taurine taken daily for three consecutive months. Immunophenotypic and molecular characterization of MNLs were determined by flow cytometry and quantitative real time PCR, respectively. In addition, serum IFN-γ level was quantified by ELISA. RESULTS: After receiving treatment with CPT combination, there was a highly significant increase in IFN- γ levels in the sera of patients when compared to basal line control samples. Additionally, the group receiving combined therapy demonstrated a downregulation in the expression levels of PD-1, in MNLs as compared to controls. MNLs' immunophenotyping revealed a significant decline in CD4+CD25+cells (regulatory T lymphocytes). Furthermore, clinicopathological characteristics revealed a highly significant impact of CPT combination on aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and alpha feto protein (AFP) levels. CONCLUSION: This study introduces a promising adjuvant CPT combined treatment as natural agents to enhance the management of HCC patients who are candidates to TACE treatment.


Assuntos
Alcaloides , Protocolos de Quimioterapia Combinada Antineoplásica , Benzodioxóis , Carcinoma Hepatocelular , Quimioembolização Terapêutica , Curcumina , Neoplasias Hepáticas , Piperidinas , Alcamidas Poli-Insaturadas , Taurina , Humanos , Carcinoma Hepatocelular/terapia , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/terapia , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/tratamento farmacológico , Alcaloides/administração & dosagem , Alcaloides/uso terapêutico , Piperidinas/administração & dosagem , Piperidinas/uso terapêutico , Quimioembolização Terapêutica/métodos , Projetos Piloto , Masculino , Curcumina/uso terapêutico , Curcumina/administração & dosagem , Feminino , Alcamidas Poli-Insaturadas/farmacologia , Alcamidas Poli-Insaturadas/administração & dosagem , Alcamidas Poli-Insaturadas/uso terapêutico , Benzodioxóis/uso terapêutico , Benzodioxóis/administração & dosagem , Pessoa de Meia-Idade , Taurina/administração & dosagem , Taurina/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Interferon gama/metabolismo , Prognóstico , Seguimentos , Leucócitos Mononucleares/metabolismo , Adulto , Idoso
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA